Venetoclax, Rituximab and Nivolumab in Combination for the Treatment of Richter ' s Transformation Arising From Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Transformed Chronic Lymphocytic Leukemia; Richter Syndrome; Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma; Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Biopsy; Procedure: Computed Tomography; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab; Procedure: Positron Emission Tomography; Biological: Rituximab; Drug: Venetoclax Sponsors: Northwestern University; National Cancer Institute (NCI); Bristol-Myers Squibb; AbbVie Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | CT Scan | Leukemia | Lymphoma | MRI Scan | PET Scan | Research | Rituxan